EXAS vs JBIO · rev $2.76B vs $868.2M cap
EXACT Sciences Corporation (EXAS) versus Jade Biosciences, Inc. (JBIO) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Jade Biosciences, Inc. (JBIO) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
JBIO does not have a complete income-statement cache yet.
EXAS currently screens at market cap $20.03B. JBIO currently screens at market cap $868.2M.
Not investment advice. Open the EXAS and JBIO stock pages for the full models.
Not investment advice.